Department of Internal Medicine, Rheumatology Clinic, Medical School, University of Ioannina, Ioannina, Greece.
Department of Pathology, Medical School, University of Ioannina, Ioannina, Greece.
Curr Rheumatol Rev. 2021;17(2):267-270. doi: 10.2174/1573397116666201119151349.
Psoriasis (Pso) is a common chronic inflammatory disease affecting the skin, both sexes, and all ages. It can be associated with other chronic inflammatory musculoskeletal disorders and certain drugs, including tumor necrosis factor α (TNFα) antagonists.
A 64-year-old man with seronegative rheumatoid arthritis (RA) refractory to leflunomide and prednisone was treated with SB-4 (Benepali), an etanercept biosimilar 50mg/week subcutaneously. He responded well to the treatment, but a year later, he developed erythematous skin eruptions affecting mainly in the palms of both hands. Skin biopsy showed a picture compatible with Pso. SB-4 was discontinued, and the skin lesions disappeared with the addition of topical steroid therapy. This is the only case of psoriatic skin lesions associated with SB-4 treatment.
Thus, we review and discuss the relevant literature of Pso cases related to SB-4 and other anti-TNFα biosimilars. Rheumatologists dealing with patients on anti-TNFα biosimilars should be aware of and recognize these complications.
银屑病（Pso）是一种常见的慢性炎症性疾病，影响皮肤，男女均可患病，且各年龄段均可发病。它可能与其他慢性炎症性肌肉骨骼疾病和某些药物有关，包括肿瘤坏死因子α（TNFα）拮抗剂。
一名 64 岁男性，患有血清阴性类风湿关节炎（RA），对来氟米特和泼尼松耐药，接受 SB-4（Benepali）治疗，即一种每周皮下注射 50mg 的依那西普生物类似药。他对治疗反应良好，但一年后，他出现了主要影响双手手掌的红斑性皮肤疹。皮肤活检显示与银屑病一致的图像。停用 SB-4 后，加用局部类固醇治疗，皮肤病变消失。这是唯一一例与 SB-4 治疗相关的银屑病皮肤病变的病例。
因此，我们复习并讨论了与 SB-4 和其他抗 TNFα 生物类似药相关的 Pso 病例的相关文献。处理接受抗 TNFα 生物类似药治疗的患者的风湿病学家应了解并认识到这些并发症。
